Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q1 2026 · 10-Q
Revenue$2.00K$2.00K−71.4% vs Q1 2025 Net Income-$24.15M-$24.15MN/M vs Q1 2025 EPS Diluted-$1.10-$1.10N/M vs Q1 2025 Operating Income-$44,261,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Free Cash Flowderived-$38,599,000N/M Margins · derivedOperating margin-2213050.0%−1393521.4 pt vs Q1 2025
Net margin-1207650.0%−462007.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end